Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-27T12:40:12.043Z Has data issue: false hasContentIssue false

Chapter 41 - Medical Management of Benign Prostatic Hyperplasia

from Section 5 - Medical and Surgical Management of Issues of Male Health

Published online by Cambridge University Press:  06 December 2023

By
Christopher Martin ,
Laurel Mast  and
Stephen Summers
Edited by
Douglas T. Carrell ,
Alexander W. Pastuszak  and
James M. Hotaling
Douglas T. Carrell
Affiliation:
Utah Center for Reproductive Medicine
Alexander W. Pastuszak
Affiliation:
University of Utah
James M. Hotaling
Affiliation:
Utah Center for Reproductive Medicine
Get access

Summary

Benign prostatic hyperplasia is the most common benign neoplasm in males in the United States. It is characterized by lower urinary tract symptoms: weak stream, urinary frequency, urgency, incomplete emptying, hesitancy, nocturia, and acute urinary retention. These symptoms are generally slowly progressive and left untreated can cause irreversible bladder damage. Diagnosis is mostly clinical and based on symptomatology; however, the use of some objective tests can be helpful. Treatment options include lifestyle modification as well as a variety of different pharmacologic agents.

Keywords

BPHmen’s healthLUTSbenign prostatic hyperplasialower urinary tract symptomsbladderprostatesphincter complexurethra
Type
Chapter
Information
Men's Reproductive and Sexual Health Throughout the Lifespan
An Integrated Approach to Fertility, Sexual Function, and Vitality
 , pp. 323 - 328
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wei, JT, Calhoun, E, Jacobsen, SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256–1261.CrossRefGoogle ScholarPubMed
Lim, KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148–151.Google Scholar
McVary, KT, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–1803.Google Scholar
Patel, ND, Parsons, JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014;30(2):170–176.Google Scholar
Villers, A, Steg, A, Boccon-Gibod, L. Anatomy of the prostate: review of the different models. Eur Urol. 1991;20(4):261–268.Google Scholar
McNeal, JE. Normal histology of the prostate. Am J Surg Pathol. 1988;12(8):619–633.CrossRefGoogle ScholarPubMed
Carson, C, 3rd, Rittmaster, R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(4 Suppl. 1):2–7.Google Scholar
Loeb, S, et al. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol. 2009;182(4):1458–1462.CrossRefGoogle ScholarPubMed
Bellucci, CHS, et al. Increased detrusor collagen is associated with detrusor overactivity and decreased bladder compliance in men with benign prostatic obstruction. Prostate Int. 2017;5(2):70–74.Google Scholar
Aslan, G, et al. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl. 2006;52(3):155–162.CrossRefGoogle ScholarPubMed
McVary, KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(Suppl. 5):S122–S128.Google ScholarPubMed
Weiss, JP, Everaert, K. Management of nocturia and nocturnal polyuria. Urology. 2019;133s:24–33.Google Scholar
Reynard, JM, et al. The ICS-‘BPH’ Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol. 1998;82(5):619–623.Google Scholar
Stone, BV, et al. Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men. BJU Int. 2017;119(2):298–304.CrossRefGoogle Scholar
Parsons, JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178(2):395–401.CrossRefGoogle ScholarPubMed
Kristal, AR, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;167(8):925–934.Google Scholar
Parsons, JK, Im, R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol. 2009;182(4):1463–1468.Google Scholar
Abrams, P, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009;181(4):1779–1787.Google Scholar
Fowke, JH, et al. Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. BJU Int. 2013;111(1):122–128.Google Scholar
Parsons, JK, et al. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study. Eur Urol. 2011;60(6):1173–1180.CrossRefGoogle ScholarPubMed
Parsons, JK, et al. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2013;189(Suppl. 1):S102–S106.Google Scholar
Wein, AJ. Diagnosis and treatment of the overactive bladder. Urology. 2003;62(5 Suppl. 2):20–27.CrossRefGoogle ScholarPubMed
Wuerstle, MC, et al. Contribution of common medications to lower urinary tract symptoms in men. Arch Intern Med. 2011;171(18):1680–1682.Google Scholar
Bent, S, et al. Saw palmetto for benign prostatic hyperplasia. N Eng J Med. 2006;354(6):557–566.Google Scholar
Lepor, H. Medical treatment of benign prostatic hyperplasia. Rev Urol. 2011;13(1):20–33.Google Scholar
Bragg, R, et al. Mirabegron: a beta-3 agonist for overactive bladder. Consult Pharm. 2014;29(12):823–837.Google Scholar
Lepor, H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2006;8(Suppl. 4):S3–S9.Google Scholar
Laydner, HK, et al. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU Int. 2011;107(7):1104–1109.Google Scholar
McConnell, JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–2398.Google Scholar
Christou, CD, et al. Intraoperative floppy iris syndrome: updated perspectives. Clin Ophthalmol. 2020;14:463–471.Google Scholar
Kirby, RS, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119–126.Google Scholar
Roehrborn, CG, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131.Google Scholar
Nickel, JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6(Suppl. 9):S31–S39.Google Scholar
Boyle, P, Gould, AL, Roehrborn, CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996;48(3):398–405.Google Scholar
Liu, L, et al. Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med. 2016;13(9):1297–1310.Google Scholar
Gonzalez, AN, et al. The prevalence of bladder cancer during cystoscopy for asymptomatic microscopic hematuria. Urology. 2019;126:34–38.Google Scholar
Davis, R, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188(6 Suppl.):2473–2481.Google Scholar
Puchner, PJ, Miller, MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol. 1995;154(5):1779–1782.CrossRefGoogle ScholarPubMed
Andriole, GL, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–1202.CrossRefGoogle ScholarPubMed
Thompson, IM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369(7):603–610.Google Scholar
Herbison, P, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003;326(7394):841–844.CrossRefGoogle ScholarPubMed
Feinberg, M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993;3(4):335–348.Google Scholar
Gray, SL, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407.Google Scholar
Wennberg, AMV, et al. Sleep disturbance, cognitive decline, and dementia: a review. Semin Neurol. 2017;37(4):395–406.Google Scholar
Foster, HE, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019;202(3):592–598.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×